NCT01859455View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
HypercholesterolemiaLDL Cholesterol
Interventions
DRUG

LGT209 50 mg

Active experimental drug

DRUG

LGT209 300 mg

Active experimental drug

DRUG

Placebo

Placebo comparator

DRUG

Statins (atorvastatin or simvastatin)

Stable doses of atorvastatin or simvastatin

Trial Locations (2)

33025

Novartis Investigative Site, Miramar

33901-8144

Novartis Investigative Site, Fort Myers

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY